Systemic treatment of patients with locally advanced or metastatic cho-langiocarcinoma – an Austrian expert consensus statement.

Taghizadeh, H; Djanani, A; Eisterer, W; Gerger, A; Gruenberger, B; Gruen-berger, T; Rumpold, H; Weiss, L; Winder, T; Woll, E; Prager, GW. Front Oncol. 2023 Aug 30:13:1225154. doi: 10.3389/fonc.2023.1225154. eCollection 2023.

Prognostic value of [18F]FDG PET/CT on treatment response and pro-gression-free survival of gastroesophageal cancer patients undergoing perioperative FLOT chemotherapy.

Mirshahvalad, SA; Seyedinia, SS; Huemer, F; Schweighofer-Zwink, G; Koch, O; Hitzl, W; Weiss, L; Emannuel, K; Greil, R; Pirich, C; Beheshti, M. Eur J Radiol. 2023 Jun:163:110843. doi: 10.1016/j.ejrad.2023.110843. Epub 2023 Apr 20.

Inactivation of TRPM7 Kinase Targets AKT Signaling and Cyc-looxygenase-2 Expression in Human CML Cells.

Hoeger, B; Nadolni, W; Holting, K; Hampe, S; Fraticelli, M; Zaborsky, N; Imm-ler, R; Chubanov, V; Geisberger, R; Greil, R; Sperandio, M; Boekhoff, I; Gu-dermann, T; Zierler, S. Function, Volume 4, Issue 6, 2023, zqad053, https://doi.org/10.1093/function/zqad053

Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial.

Antonarakis ES; Park SH; Goh JC; Shin SJ; Lee JL; Mehra N; McDermott R; Sala-Gonzalez N; Fong PC; Greil R; Retz M; Sade JP; Yanez P; Huang YH; Begbie SD; Gafanov RA; De Santis M; Rosenbaum E; Kolinsky MP; Rey F; Chiu KY; Roubaud G; Kramer G; Sumitomo M; Massari F; Suzuki H; Qiu P; Zhang J; Kim J; Poehlein CH; Yu EY. J Clin Oncol. 2023 Aug 1;41(22):3839-3850. doi: 10.1200/JCO.23.00233. Epub 2023 Jun 8.PMID: 37290035

Spatial predictors of immunotherapy response in triple-negative breast cancer.

Wang, XQ; Danenberg, E; Huang, CS; Egle, D; Callari, M; Bermejo, B; Dugo, M; Zamagni, C; Thill, M; Anton, A; Zambelli, S; Russo, S; Ciruelos, EM; Greil, R; Gyorffy, B; Semiglazov, V; Colleoni, M; Kelly, CM; Mariani, G; Del Mastro, L; Biasi, O; Seitz, RS; Valagussa, P; Viale, G; Gianni, L; Bianchini, G; Ali, HR. Nature. 2023 Sep;621(7980):868-876. doi: 10.1038/s41586-023-06498-3. E-pub 2023 Sep 6.

Comparison of gemcitabine plus oxaliplatin versus gemcitabine plus nab-paclitaxel as first-line chemotherapy for advanced pancreatic adeno-carcinoma: A single-center retrospective analysis.

Schlick, K; Gantschnigg, A; Seymer, A; Huemer, F; Greil, R; Weiss, L. Cancer Med. 2023 Aug;12(16):16997-17004. doi: 10.1002/cam4.6334. Epub 2023 Aug 3.

Cox proportional hazards deep neural network identifies peripheral blood complete remission to be at least equivalent to morphologic complete remission in predicting outcomes of patients treated with azacitidine-A prospective cohort study by the AGMT.

Pleyer, L; Vaisband, M; Drost, M; Pfeilstöcker, M; Stauder, R; Heibl, S; Sill, H; Girschikofsky, M; Stampfl-Mattersberger, M; Pichler, A; Hartmann, B; Petzer, A; Schreder, M; Schmitt, CA; Vallet, S; Melchardt, T; Zebisch, A; Pichler, P; Zaborsky, N; Machherndl-Spandl, S; Wolf, D; Keil, F; Hasenauer, J; Larcher-Senn, J; Greil, R. Am J Hematol. 2023 Nov;98(11):1685-1698. doi: 10.1002/ajh.27046. Epub 2023 Aug 7.

Management of metastatic colorectal cancer in patients ≥70 years – a single center experience.

Huemer, F; Dunkl, C; Rinnerthaler, G; Schlick, K; Heregger, R; Emmanuel, K; Neureiter, D; Klieser, E; Deutschmann, M; Roeder, F; Greil, R; Weiss, L. Front Oncol. 2023 Jul 25:13:1222951. doi: 10.3389/fonc.2023.1222951. eCollection 2023.

Erythropoiesis-stimulating agents-benefits and harms in the treatment of anemia in cancer patients.

Heregger, R; Greil, R. memo 16, 259–262 (2023). https://doi.org/10.1007/s12254-023-00902-4.

Validation of genetic variants from NGS data using deep convolutional neural networks.

Vaisband, M; Schubert, M; Gassner, FJ; Geisberger, R; Greil, R; Zaborsky, N; Hasenauer, J. BMC Bioinformatics. 2023 Apr 20;24(1):158. doi: 10.1186/s12859-023-05255-7.